The awards for work published in 2019 are presented to:

Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, Kris Jardon, Andrés Redondo, Richard G Moore, Christof Vulsteke, Roisin E O’Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley F Haggerty, Maria J Rubio-Pérez, Mark S Shahin, Giorgia Mangili, William H Bradley, Ilan Bruchim, Kaiming Sun, Izabela A Malinowska, Yong Li, Divya Gupta, Bradley J Monk and the PRIMA/ENGOT-OV26/GOG-3012 Investigators for the following publication: “Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer”, published in the New England Journal of Medicine in 2019.

Jesse J Salk, Kaitlyn Loubet-Senear , Elisabeth Maritschnegg , Charles C Valentine , Lindsey N Williams , Jacob E Higgins, Reinhard Horvat , Adriaan Vanderstichele , Daniela Nachmanson , Kathryn T Baker, Mary J Emond, Emily Loter, Maria Tretiakova, Thierry Soussi, Lawrence A Loeb, Robert Zeillinger, Paul Speiser, and Rosa Ana Risques for the following publication: “Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan”, published in Cell Reports 2019 :

Prior recipients of the Award:

 

Dr. Kathleen N. Moore, at the Stephenson Cancer Center of the University of Oklahoma, on behalf of her collaborators for the publication entitled “Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer”, published in the New England Journal of Medicine 2018.

 

 

Michael Anglesio, Nikolas Papadopoulus and Ayse Ayhan on behalf of their colleagues for the following publication “Cancer-Associated Mutations in Endometriosis without Cancer”, published in the New England Journal of Medicine 2017.

Ole-Erik Iversen on behalf of his collaborators for the following publication; “Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women”, published in JAMA 2016.

Anne Maree Patch, Elizabeth Christie, Dariush Etemadmoghadam and Dale W Garsed on behalf of their co-authors for the manuscript entitled: ‘Whole-genome characterization of chemoresistant ovarian cancer”, published in Nature 2015.

Dr. Joyce F. Liu,  of  the Dana Farber Cancer Institute, for the paper entitled: “Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study” published in Lancet Oncol 2014.

Nikolaus Dietrich Schultz, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY. For the paper entitled “Integrated genomic characterization of endometrial carcinoma”, published in Nature 2013.

Brooke Winner, MD of Washington University School of Medicine for the paper entitled “Effectiveness of Long-Acting Reversible Contraception”, published in the New England Journal of Medicine in 2012.

Jonathan Ledermann, MD, of the University College London for the paper entitled “Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer” published in the New England Journal of Medicine 2012.

Rebecca L. Stone, MD, of the University of Texas M.D. Anderson Cancer Center for the paper entitled “Paraneoplastic Thrombocytosis in Ovarian Cancer” published in the New England Journal of Medicine 2012.